Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Treatment With Brigatinib in Patients With Advanced NSCLC Harboring an ALK Rearrangement by LAT at the Time of Best Response: A Multicenter Open Phase Two Trial (OPTALK)

NCT06620835 is registered in ClinicalTrials.gov with Groupe Francais De Pneumo-Cancerologie as lead sponsor.

NCT NCT06620835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06620835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Treatment With Brigatinib in Patients With Advanced NSCLC Harboring an ALK Rearrangement by LAT at the Time of Best Response: A Multicenter Open Phase Two Trial (OPTALK)
Lead sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Phase 2
Overall status
Recruiting
Start date
June 19, 2025
Completion date
October 1, 2030
Enrollment
45 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc